Biocorp
| (at previous day's close) |
| Market Cap. |
69.21 |
m |
| Shares In Issue |
2.96 |
m |
| Prev. Close |
23.50 |
|
| PE Ratio |
-81.68 |
|
| Dividend Yield |
- |
% |
| EPS – basic |
-0.29 |
c |
| Dividend PS |
- |
c |
| Dividend Cover |
- |
|
| Cash Flow PS |
-0.93 |
c |
| Return On Equity (ROE) |
-22.81 |
% |
| Operating Margin |
- |
% |
| PEG Factor |
- |
|
| EPS Growth Rate |
- |
% |
| Dividend PS Growth Rate |
- |
% |
| Net Debt |
-1.09 |
m |
| Gross Gearing |
41.13 |
% |
| Quick Assets |
6.92 |
m |
| Net Working Cap |
7.96 |
m |
| Intangibles / Fixed Assets |
11.19 |
% |
| Turnover PS |
0.83 |
c |
| Pre-Tax Profit PS |
-0.00 |
c |
| Retained Profit PS |
- |
c |
| Cash PS |
203.71 |
c |
| Net Cash PS |
67.19 |
c |
| Net Tangible Asset Value PS* |
9.10 |
c |
| Net Asset Value PS |
405.57 |
c |
| Spread |
0.10 (0.43%) |
|
| *Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies. |
|
Biocorp Balance Sheet (31 Dec 2015)
Biocorp Share Price
| Sample Period † |
High |
Low |
| 1 week |
21.80 |
25.00 |
| 4 weeks |
19.80 |
25.00 |
| 12 weeks |
15.10 |
25.00 |
| 1 year |
13.40 |
25.00 |
Biocorp (5 years)
|
Biocorp Historic Returns
| Period * |
Open |
Change |
% |
Open Avg. |
Avg. Daily Vol [m] |
Total Vol. [m] |
VWAP |
| 1 week |
22.50 |
0.90 |
4.00 |
23.54 |
6,784.00 |
|
23.53 |
| 4 weeks |
21.30 |
2.10 |
9.86 |
21.97 |
4,490.00 |
|
22.31 |
| 12 weeks |
17.15 |
6.25 |
36.44 |
20.25 |
5,041.00 |
|
20.76 |
| 26 weeks |
23.20 |
0.20 |
0.86 |
19.07 |
4,489.00 |
|
18.89 |
| 1 year |
32.90 |
-9.50 |
-28.88 |
24.95 |
3,986.00 |
|
24.01 |
| 3 years |
14.20 |
9.20 |
64.79 |
25.17 |
4,556.00 |
|
24.02 |
| 5 years |
11.95 |
11.45 |
95.82 |
19.21 |
3,311.00 |
|
21.75 |
| * periods calculated are whole weeks rather than calendar months |
|
|
Biocorp Key Management Ratio
|
Biocorp Investment Ratios
| (Market value analysis) at previous day's close |
|
PQ Ratio |
-17.79 |
|
|
PE Ratio |
-81.68 |
|
|
Tobin's Q Ratio |
- |
|
|
Tobin's Q Ratio (excl. intangibles) |
- |
|
|
Dividend Yield |
- |
% |
|
Market-to-Book Ratio |
5.79 |
|
|
Price-to-Pre-Tax Profit PS |
-659,385.75 |
|
|
Price-to-Retained Profit PS |
- |
|
|
Price-to-Cash Flow PS |
-25.21 |
|
|
Price-to-Sales PS |
28.23 |
|
|
Price-to-Net Tangible Asset Value PS |
2.58 |
|
|
Price-to-Cash PS |
0.12 |
|
|
Net Working Capital PS |
2.69 |
|
|
Price Pct to Working Capital PS |
8.73 |
% |
|
Earnings Yield |
- |
% |
|
Average PE |
- |
|
|
Years in Average PE |
- |
|
|
PE to PE average |
- |
% |
|
Biocorp Financial Ratios
| (Leverage Ratios) |
|
Debt Ratio |
-22.13 |
% |
|
Debt-to-Equity Ratio |
-0.15 |
|
|
Debt-to-Equity Ratio (excl. Intgbl) |
-0.27 |
|
|
Debt-to-Equity Market Value |
-0.02 |
|
|
Net Gearing |
-9.10 |
% |
|
Net Gearing (excl. Intangibles) |
-12.15 |
% |
|
Gross Gearing |
41.13 |
% |
|
Gross Gearing (excl. Intangibles) |
54.91 |
% |
|
Gearing Under 1 Year |
33.66 |
% |
|
Gearing Under 1 Year (excl. Intgbl) |
44.94 |
% |
|
Assets / Equity |
1.70 |
|
|
Cash / Equity |
0.85 |
|
|
(Liquidity Ratios) |
|
Net Working Capital to Total Assets |
66.34 |
% |
|
Current Ratio |
0.67 |
|
|
Quick Ratio (Acid Test) |
0.56 |
|
|
Liquidity Ratio |
1.49 |
|
|
Cash & Equiv / Current Assets |
223.91 |
% |
|
(Solvency Ratios) |
|
Enterprise Value |
640.84 |
m |
|
Sales |
-1.12 |
|
|
CFO / Attributable Profit |
- |
|
|
CFO / Assets |
-0.00 |
|
|
CFO / Debt |
-0.00 |
|
|
Total Debt / Equity Market Value |
0.07 |
|
|
Total Debt / Sales |
2.00 |
|
|
Total Debt / Pre-Tax Profit |
-4,680,226.27 |
|
|
Total Debt |
4.93 |
m |
|
Total Debt / Net Current Assets |
0.62 |
% |
|
(Dodds – Graham Ratios) |
|
|
|
3 yr Compound Earnings Growth |
- |
% |
|
5 yr Compound Earnings Growth |
- |
% |
|
10 yr Compound Earnings Growth |
- |
% |
|
Earn drops > 5% in 10yrs |
- |
|
|
Beta (60-Mnth) |
Beta (36-Mnth) |
| - |
- |
|
Alpha (60-Mnth) |
Alpha (36-Mnth) |
| - |
- |
|
Biocorp Operating Ratios
| (Profitability Ratios) |
|
Return On Capital Employed (ROCE) |
- |
% |
|
Return On Assets (ROA) |
- |
% |
|
Net Profit Margin |
- |
% |
|
Assets Turnover |
- |
|
|
Return On Equity (ROE) |
-22.81 |
% |
|
Return On Investment (ROI) |
- |
% |
|
Dividend Payout Ratio |
- |
% |
|
Plowback Ratio |
- |
% |
|
Growth from Plowback Ratio |
- |
% |
|
Net Income of Revenues |
- |
% |
| (Asset Utilisation Multiples) |
|
Shareholders Equity Turnover |
- |
|
|
Fixed Assets Turnover |
- |
|
|
Current Assets Turnover |
- |
|
|
Net Working Capital Turnover |
- |
|
|
Inventory Turnover |
- |
|
| (Other Operating Ratios) |
|
Total Assets-to-Sales |
- |
|
|
Debtors-to-Sales |
- |
% |
|
Debt Collection Period |
- |
Days |
|
Biocorp Dividends
| Type |
Curr. |
Dividend Amount |
Period Start |
Period End |
Total Dividend Amount |
| Final |
EUR |
- |
31 Dec 2014 |
31 Dec 2015 |
- |
| Final |
EUR |
- |
31 Dec 2013 |
31 Dec 2014 |
- |
|
Biocorp Fundamentals
|
| |
31 Dec 2012 (EUR) |
|
31 Dec 2013 (EUR) |
|
31 Dec 2014 (EUR) |
|
31 Dec 2015 (EUR) |
|
|
Turnover |
- |
100.00% |
|
- |
100.00% |
|
1.65 |
100.00% |
|
2.46 |
100.00% |
m |
|
Pre Tax Profit |
- |
-% |
|
- |
-% |
|
-0.30 |
-18.18% |
|
-1.05 |
-42.81% |
m |
|
Attributable Profit |
- |
-% |
|
- |
-% |
|
- |
-% |
|
- |
-% |
m |
|
Retained Profit |
- |
-% |
|
- |
-% |
|
- |
-% |
|
- |
-% |
m |
|
Eps – Basic |
- |
|
|
- |
|
|
0.31 |
|
|
-0.29 |
|
|
|
Eps – Diluted |
- |
|
|
- |
|
|
0.31 |
|
|
-0.29 |
|
|
|
Dividends per Share |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biocorp Balance Sheet
| |
31 Dec 2012 (EUR) |
|
31 Dec 2013 (EUR) |
|
31 Dec 2014 (EUR) |
|
31 Dec 2015 (EUR) |
|
|
|
|
|
|
  |
|
  |
|
|
|
| |
31 Dec 2012 (EUR) |
|
31 Dec 2013 (EUR) |
|
31 Dec 2014 (EUR) |
|
31 Dec 2015 (EUR) |
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed assets |
- |
-% |
|
- |
-% |
|
- |
-% |
|
- |
-% |
m |
Intangibles |
- |
-% |
|
- |
-% |
|
3.29 |
61.54% |
|
3.01 |
25.10% |
m |
|
Fixed Investments |
- |
-% |
|
- |
-% |
|
0.04 |
0.78% |
|
0.27 |
2.24% |
m |
Current Assets – Other |
- |
-% |
|
- |
-% |
|
1.04 |
19.36% |
|
1.38 |
11.52% |
m |
|
Stocks |
- |
-% |
|
- |
-% |
|
0.46 |
8.59% |
|
0.41 |
3.44% |
m |
|
Debtors |
- |
-% |
|
- |
-% |
|
0.45 |
8.50% |
|
0.90 |
7.48% |
m |
Cash & securities |
- |
-% |
|
- |
-% |
|
0.07 |
1.22% |
|
6.03 |
50.23% |
m |
|
Other assets |
- |
-% |
|
- |
-% |
|
0.00 |
0.03% |
|
0.00 |
0.01% |
m |
|
|
|
TOTAL |
- |
-% |
|
- |
-% |
|
5.35 |
100.00% |
|
12.00 |
100.00% |
m |
|
|
LIABILITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
Creditors – Short |
- |
-% |
|
- |
-% |
|
3.84 |
958.63% |
|
4.04 |
57.18% |
m |
Creditors – Long |
- |
-% |
|
- |
-% |
|
1.11 |
276.23% |
|
0.90 |
12.68% |
m |
|
|
TOTAL |
- |
-% |
|
- |
-% |
|
4.95 |
1,234.86% |
|
4.93 |
69.86% |
m |
|
|
EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority Interest |
- |
-% |
|
- |
-% |
|
-0.40 |
-100.00% |
|
-7.06 |
-100.00% |
m |
|
Capital Reserves |
- |
-% |
|
- |
-% |
|
0.40 |
100.00% |
|
7.06 |
100.00% |
m |
|
TOTAL |
- |
-% |
|
- |
-% |
|
0.40 |
100.00% |
|
7.06 |
100.00% |
m |
|
|
Biocorp Cash Flow Statement
|
31 Dec 2012 (EUR) |
|
31 Dec 2013 (EUR) |
|
31 Dec 2014 (EUR) |
|
31 Dec 2015 (EUR) |
|
|
Operating CF |
- |
|
- |
|
-1.45 |
|
-2.76 |
|
|
Investing CF |
- |
|
- |
|
-0.60 |
|
-0.71 |
|
|
Financial CF |
- |
|
- |
|
2.15 |
|
9.46 |
|
|
Net change CF |
- |
|
- |
|
0.10 |
|
6.00 |
|
|
|
|
|
|
|
|
|
|
|
Biocorp Employee Data
|
31 Dec 2012 (EUR) |
|
31 Dec 2013 (EUR) |
|
31 Dec 2014 (EUR) |
|
31 Dec 2015 (EUR) |
|
|
Number of employees |
- |
|
- |
|
21.00 |
|
- |
|
|
Sales per employee |
- |
|
- |
|
0.08 |
|
- |
m |
|
|
|
|
|
|
|
|
|
|